Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7880)	12/3/1998 7:54:00 AM
From: Robert S.	Read Replies (3) \| Respond to of 17367

From my previous post: >RobertK, I was mistaken in stating that BPI did not have an effect upon cytokines; if this is beneficial to a patient, however, remains a matter of controversy. Since cytokines play both pathogenic and protective roles, inhibiting the inflammatory response may not be the best therapeutic course of action. And what of the other mediators and components? Undetected L-forms? Finally, the heterogeneous nature and timing of mediator release and balance, when coupled with the factors above, illustrates why successfully combating a complex, multifactorial malady (e.g., sepsis) is so extraordinarily difficult.< Your response: IMO those views you posted are views and remain views until the facts are known. I find no fault in those in the "view" context. These "views" are not held by a bunch of street-corner urchins; rather, they are held by highly educated and trained medical professionals. Such "views" evolve in response to the preponderant evidence; the perspectives formed are not without validity. Does this guarantee that the "views" of the medical community are correct? No. But the odds are good that at least some of the contradictory evidence above will prove problematic in treating the sepsis syndrome.